Generic Semaglutide in India: Affordable Treatment Options
Learn how the advent of Generic Semaglutide in India will change the landscape of weight-loss and diabetes medications.
Aspen Pharmacare Asset Disposals: Future Opportunities
Learn about potential Aspen Pharmacare asset disposals aimed at optimising the company's global operations for greater profitability.
Aspen Pharmacare Debt-Free: Strategic Shift To GLP-1 Injectables
Aspen Pharmacare Debt-Free marks a pivotal moment in its history as it shifts focus toward GLP-1 injectables like semaglutide.
Eli Lilly 2026 Guidance Signals Momentum In Obesity Care
Eli Lilly has forecast 2026 profit and revenue above Wall Street expectations, reinforcing how fast the obesity market is reshaping Big Pharma growth plans. The recent Eli Lilly 2026 Guidance reflects the company’s confidence in strong future performance. The company also beat estimates for fourth-quarter earnings, helped by strong demand for its injectable weight-loss and…...
Roche CT-388 Obesity Drug Posts 22.5% Weight Loss
Roche CT-388 Obesity Drug shows up to 22.5% placebo-adjusted weight loss at 48 weeks, as Roche moves into Phase 3 to challenge Lilly and Novo.
Generic Semaglutide Set to Disrupt Global GLP‑1 Market
Aspen Pharmacare is lining up a generic semaglutide launch in Canada, promising big discounts, and widening GLP-1 access.
GLP-1 Weight Loss Drugs Reshape Obesity Care In South Africa
GLP-1 weight loss drugs like Mounjaro and Wegovy are transforming obesity treatment in SA amid rising health concerns and systemic barriers.
GLP-1 Medicines Review: South Africa Moves to Expand Access
NEMLC begins a GLP-1 medicines review to assess affordability and potential inclusion in the public health sector for diabetes and obesity
Illegal weight loss injections: The rising black market crisis
Illegal weight loss injections are flooding the local market as high costs and obesity rates drive a dangerous market for GLP-1 agonists.
Surge in Illicit Medicines Threatens Public Health
Understand the impact of the surge in illicit medicines on public health in South Africa and the measures being taken to protect patients.